Trial reportDiabetes care2010
Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial.
Trial report in Diabetes care, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Effect of cannabis and subproducts on anthropometric measures: a systematic review and meta-analysis.International journal of obesity (2005) · 2024Pooled it
- Mood Disorders, Metabolic Bariatric Surgery, and Weight Loss Pharmacotherapy: a Research Update.Current obesity reports · 2025Review
- Changes in plasma endocannabinoids concentrations correlate with 18F-FDG PET/MR uptake in brown adipocytes in humans.Frontiers in molecular biosciences · 2023Article
- Hepatic targeting of the centrally active cannabinoid 1 receptor (CBJournal of controlled release : official journal of the Controlled Release Society · 2023Article
- The effects of cannabis and cannabinoids on the endocrine system.Reviews in endocrine & metabolic disorders · 2022Review
- Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy.World journal of diabetes · 2022Review
- Metabolic Consequences of Gestational Cannabinoid Exposure.International journal of molecular sciences · 2021Review
- The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling.Cellular and molecular life sciences : CMLS · 2020Article
- Anti-obesity therapy with peripheral CB1 blockers: from promise to safe(?) practice.International journal of obesity (2005) · 2020Review
- Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.Biomolecules · 2020Review
- Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol.Frontiers in endocrinology · 2020Review
- Druggable Targets in Endocannabinoid Signaling.Advances in experimental medicine and biology · 2020Review
- Review
- Countering the Modern Metabolic Disease Rampage With Ancestral Endocannabinoid System Alignment.Frontiers in endocrinology · 2019Article
- Endocannabinoid regulation of β-cell functions: implications for glycaemic control and diabetes.Diabetes, obesity & metabolism · 2016Review
- Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.Cell stress & chaperones · 2016Article
- Diacylglycerol Lipase α Knockout Mice Demonstrate Metabolic and Behavioral Phenotypes Similar to Those of Cannabinoid Receptor 1 Knockout Mice.Frontiers in endocrinology · 2015Article
- Modulating the endocannabinoid system in human health and disease--successes and failures.The FEBS journal · 2013Review
- The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications.The American journal of pathology · 2012Review
- The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications.British journal of pharmacology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OBJECTIVE To examine the efficacy and safety of rimonabant, a selective cannabinoid receptor type-1 antagonist, in patients with type 2 diabetes receiving insulin monotherapy. RESEARCH DESIGN AND METHODS Patients (n = 368; A1C > or =7%) were randomized to 20 mg/day rimonabant or placebo in this 48-week, double-blind, placebo-controlled multicenter trial. Change in baseline A1C to week 48 (primary outcome) and changes in body weight, waist circumference, and lipid levels (secondary outcomes) were assessed. RESULTS Rimonabant significantly reduced baseline A1C versus placebo (-0.89 vs. -0.24%; P < 0.0001), and significantly greater improvements were observed in cardiometabolic risk factors. More rimonabant patients achieved >10% reduction in mean total daily insulin dose versus placebo (P = 0.0012), and fewer required rescue medication (P < 0.0001). Hypoglycemia, nausea, dizziness, anxiety, and depression were more frequent with rimonabant. CONCLUSIONS Rimonabant improved glycemic control and cardiometabolic risk factors in patients with type 2 diabetes receiving insulin.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.